NuNerve
Manufacturing · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
PO Box 6069, St Lucia, Queensland, 4067,...Website
www.nunerve.comRevenue
<$5 MillionIndustry
ZI Rank: 1
About NuNerve
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NuNerve your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when NuNerve launches new products
Funding: Get notified immidiatlly once NuNerve has new funding data
Click to see if NuNerve had a recent Job posting/layoffs
NuNerve, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if NuNerve has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at NuNerve
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on NuNerve recently announced quarterly report
Check out if NuNerve is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
NuNerve is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NuNerve is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NuNerve.
NuNerve Tech Stack
A closer look at the technologies used by NuNerve
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding NuNerve
NuNerve is a pioneering biotechnology company focused on developing innovative therapies for neurological disorders, particularly motor neuron disease (MND) and amyotrophic lateral sclerosis (ALS). Their lead clinical candidate, NUN-004, is a modified form of EphA4-Fc that has shown promising therapeutic effects in clinical trials. The company aims... Read More
